Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Jacques Body

Showing results (111-120 of 133) with videos related to

Pageof 14
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 27, 2013
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acidRoger von Moos, Jean-Jacques Body, Blair Egerdie, et al.
Calcified Tissue International|March 27, 2025
Bone Effects of Anti-Cancer Treatments in 2024Marie Teissonnière, Mathieu Point, Emmanuel Biver, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind studyAlison T Stopeck, Allan Lipton, Jean-Jacques Body, et al.
Archives of Osteoporosis|January 20, 2019
Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trialSalvatore Minisola, Fernando Marin, David L Kendler, et al.
Cancer|January 28, 2003
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastasesJean-Jacques Body, Philip Greipp, Robert E Coleman, et al.
The Journal of Clinical Endocrinology and Metabolism|October 26, 2020
Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTSElena Tsourdi, M Carola Zillikens, Christian Meier, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 13, 2018
Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO TrialPiet Geusens, Fernando Marin, David L Kendler, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 4, 2015
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancerAlison T Stopeck, Karim Fizazi, Jean-Jacques Body, et al.
Lancet (London, England)|November 14, 2017
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trialDavid L Kendler, Fernando Marin, Cristiano A F Zerbini, et al.
Journal of Internal Medicine|December 13, 2022
Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalaciaSuzanne M Jan de Beur, Salvatore Minisola, Wei-Bo Xia, et al.
Pageof 14

Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 27, 2013
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acidRoger von Moos, Jean-Jacques Body, Blair Egerdie, et al.
Calcified Tissue International|March 27, 2025
Bone Effects of Anti-Cancer Treatments in 2024Marie Teissonnière, Mathieu Point, Emmanuel Biver, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind studyAlison T Stopeck, Allan Lipton, Jean-Jacques Body, et al.
Archives of Osteoporosis|January 20, 2019
Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trialSalvatore Minisola, Fernando Marin, David L Kendler, et al.
Cancer|January 28, 2003
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastasesJean-Jacques Body, Philip Greipp, Robert E Coleman, et al.
The Journal of Clinical Endocrinology and Metabolism|October 26, 2020
Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTSElena Tsourdi, M Carola Zillikens, Christian Meier, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 13, 2018
Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO TrialPiet Geusens, Fernando Marin, David L Kendler, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 4, 2015
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancerAlison T Stopeck, Karim Fizazi, Jean-Jacques Body, et al.
Lancet (London, England)|November 14, 2017
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trialDavid L Kendler, Fernando Marin, Cristiano A F Zerbini, et al.
Journal of Internal Medicine|December 13, 2022
Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalaciaSuzanne M Jan de Beur, Salvatore Minisola, Wei-Bo Xia, et al.
Pageof 14